Craft

Halozyme Therapeutics

Stock Price

$50.8

2024-06-07

Market Capitalization

$6.5 B

2024-06-07

Revenue

$829.3 M

FY, 2023

Halozyme Therapeutics Summary

Company Summary

Overview
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment. The company offers its enzyme rHuPH20, which is used to facilitate the delivery of injected drugs and fluids and forms the basis of ENHANZE drug delivery technology platform that enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. In addition, the company markets Hylenex recombinant (hyaluronidase human injection), which is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs.
Type
Public
Status
Active
Founded
1998
HQ
San Diego, CA, US | view all locations
Website
https://halozyme.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Helen Torley

    Helen Torley, President, Chief Executive Officer and Member of the Board of Directors

    • Steve Knowles

      Steve Knowles, Chief Medical Officer

    • Connie L. Matsui

      Connie L. Matsui, Chairman of the Board

    • Jean-Pierre Bizzari

    Operating MetricsView all

    Patents (Europe)

    460
    11.5%

    FY, 2020

    Patents (US)

    43

    FY, 2020

    Phase II Trials Products

    1

    FY, 2020

    LocationsView all

    1 location detected

    • San Diego, CA HQ

      United States

      11388 Sorrento Valley Rd

    Halozyme Therapeutics Financials

    Summary Financials

    Revenue (Q1, 2024)
    $195.9M
    Gross profit (Q1, 2024)
    $167.6M
    Net income (Q1, 2024)
    $76.8M
    Cash (Q1, 2024)
    $164.6M
    EBIT (Q1, 2024)
    $95.5M
    Enterprise value
    $7.8B

    Blogs

    Footer menu